Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07821424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Wucao Anfu Formula as Adjunctive Treatment for Immune Checkpoint Inhibitor-Related Rash

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Immune checkpoint inhibitors have improved outcomes for patients with cancer, but immune checkpoint inhibitor-related skin rash is a common adverse event that may affect quality of life and continuation of anticancer therapy. This study aims to evaluate the efficacy and safety of Wucao Anfu Formula as an adjunctive treatment for immune checkpoint inhibitor-related rash. In this randomized controlled clinical study, eligible patients with grade 1-2 immune checkpoint inhibitor-related rash will be randomly assigned to receive standard topical corticosteroid treatment with or without Wucao Anfu Formula. The study will assess improvement of skin rash severity, symptoms, quality of life, and safety outcomes. The results may provide clinical evidence for integrative management of immune checkpoint inhibitor-related skin adverse events.
Trial Details
NCT Number NCT07821424
Lead Sponsor First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Conditions
(from sponsor)		 Immune Checkpoint Inhibitor-related Rash, Immune-related Adverse Events
Related terms Exanthema
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov